Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases

Nature Reviews Rheumatology

Volumn 12, Issue 3, 2016, Pages 169-182

  Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMINO ACID; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CYCLIC AMP; FINGOLIMOD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KYNURENINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOLIPID ANTIBODY; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAPAMYCIN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ATTENTION DEFICIT DISORDER; AUTOIMMUNE DISEASE; AUTOPHAGY; CELLULAR DISTRIBUTION; COLLAGEN-INDUCED ARTHRITIS; CYTOKINE RELEASE; DENDRITIC CELL; ENDOSOME; FATTY ACID SYNTHESIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INTERFERON PRODUCTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYSOSOME; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PATHOGENESIS; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; RHEUMATIC DISEASES;

ANIMALS; ENZYME ACTIVATION; HUMANS; PROTEIN KINASE INHIBITORS; RHEUMATIC DISEASES; TOR SERINE-THREONINE KINASES;

EID: 84959209910     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.172     Document Type: Review

References (243)

1. Vezina C., Kudelski A., & Sehgal S. N. Rapamycin (AY 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721-726 (1975
2. Sehgal S. N., & Bansback C. C. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann. NY Acad. Sci. 685, 58-67 (1993
3. Collier D. S. J., et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant. Proc. 22, 1674-1675 (1990
4. Calne R. Y., et al. Rapamycin for immunosuppression in organ allografting. Lancet 334, 227 (1989
5. Warner L. M., Adams L. M., & Sehgal S. N. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 37, 289-297 (1994
6. Fernandez D., Bonilla E., Mirza N., Niland B., & Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2983-2988 (2006
7. Cejka D., et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 62, 2294-2302 (2010
8. Bruyn G. A. W., et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3 month, double-blind, randomised, placebo-controlled, parallel-group, proof of concept study. Ann. Rheum. Dis. 67, 1090-1095 (2008
9. Foroncewicz B., Mucha K., Pàczek L., Chmura A., & Rowiński W. Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transpl. Int. 18, 366-368 (2005
10. Shah M., et al. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögrens syndrome. J. Control. Release 171, 269-279 (2013
11. Ponticos M., et al. Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheumatol. 67, 243-253 (2015
12. Tamaki Z., et al. Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts. J. Dermatol. Sci. 74, 251-259 (2014
13. Yoshizaki A., et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 62, 2476-2487 (2010
14. Chen C., et al. mTOR inhibition rescues osteopenia in mice with systemic sclerosis. J. Exp. Med. 212, 73-91 (2015
15. Su T. I., et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 60, 3821-3830 (2009
16. Terasawa A., et al. Sirolimus-eluting stent implantation for ostial stenosis of left main coronary artery after Bentall operation in aortitis syndrome. J. Cardiol. 55, 147-150 (2010
17. Furukawa Y., et al. Sirolimus-eluting stent for in stent restenosis of left main coronary artery in Takayasu arteritis. Circ. J. 69, 752-755 (2005
18. Koening C. L., Hernandez-Rodriguez J., Molloy E. S., Clark T. M., & Hoffman G. S. Limited utility of rapamycin in severe, refractory Wegeners granulomatosis. J. Rheumatol. 36, 116-119 (2009
19. Constantinescu A. R., Liang M., & Laskow D. A. Sirolimus lowers myeloperoxidase and p ANCA titers in a pediatric patient before kidney transplantation. Am. J. Kidney Dis. 40, 407-410 (2002
20. Lopez De Figueroa P., Lotz M. K., Blanco F. J., & Carames B. Autophagy activation and protection from mitochondrial dysfunction in human chondrocytes. Arthritis Rheum. 67, 966-976 (2015
21. Chauvin C., et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 33, 474-483 (2014
22. Gingras A. C., et al. Regulation of 4E BP1 phosphorylation: a novel two step mechanism. Genes Dev. 13, 1422-1437 (1999
23. Kim J. H., Yoon M. S., & Chen J. Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation. J. Biol. Chem. 284, 35425-35432 (2009
24. Nazio F., et al. MTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat. Cell. Biol. 15, 406-416 (2013
25. Alers S., Loffler A. S., Wesselborg S., & Stork B. Role of AMPK-mTOR Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol. Cell. Biol. 32, 2-11 (2012
26. Zoncu R., et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H+-ATPase. Science 334, 678-683 (2011
27. Bar-Peled L., et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340, 1100-1106 (2013
28. Sarbassov D. D., & Sabatini D. M. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 280, 39505-39509 (2005
29. Thedieck K., et al. Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells. Cell 154, 859-874 (2013
30. Fernandez D. R., et al. Activation of mTOR controls the loss of TCRζ in lupus T cells through HRES 1/Rab4 regulated lysosomal degradation. J. Immunol. 182, 2063-2073 (2009
31. Sonenberg N., & Hinnebusch A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731-745 (2009
32. Sancak Y., et al. The Rag GTPases bind Raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501 (2008
33. Desai B. N., Myers B. R., & Schreiber S. L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl Acad. Sci. USA 99, 4319-4324 (2002
34. Shor B., et al. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J. Biol. Chem. 285, 15380-15392 (2010
35. Tsang C. K., Liu H., & Zheng X. S. mTOR binds to the promoters of RNA polymerase I-and III-transcribed genes. Cell Cycle 9, 953-957 (2010
36. Ravikumar B., Imarisio S., Sarkar S., OKane C. J., & Rubinsztein D. C. Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J. Cell. Sci. 121, 1649-1660 (2008
37. Su W. C., et al. Rab5 and class III phosphoinositide 3 kinase Vps34 are involved in hepatitis C virus NS4B induced autophagy. J. Virol. 85, 10561-10571 (2011
38. Jia W., Pua H. H., Li Q. J., & He Y. W. Autophagy regulates endoplasmic reticulum homeostasis and calcium mobilization in T lymphocytes. J. Immunol. 186, 1564-1574 (2011
39. Gutierrez M. G., Munafo D. B., Beron W., & Colombo M. I. Rab7 is required for the normal progression of the autophagic pathway in mammalian cells. J. Cell Sci. 117, 2687-2697 (2004
40. Stein M. P., Feng Y., Cooper K. L., Welford A. M., & Wandinger-Ness A. Human VPS34 and p150 are Rab7 interacting partners. Traffic 4, 754-771 (2003
41. Caza T. N., et al. HRES 1/RAB4 mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann. Rheum. Dis. 73, 1887-1897 (2014
42. Talaber G., et al. HRES 1/Rab4 promotes the formation of LC3+ autophagosomes and the accumulation of mitochondria during autophagy. PLoS ONE 9, e84392 (2014
43. Telarico T., et al. HRES 1/Rab4 lupus susceptibility gene selectively regulates mammalian target of rapamycin complexes 1 and 2 in T lymphocytes. Arthritis Rheum. Abstr. 63 (Suppl. 10), 2358 (2011
44. Chamberlain M. D., Berry T. R., Pastor M. C., & Anderson D. H. The p85α subunit of phosphatidylinositol 3? kinase binds to and stimulates the GTPase activity of Rab proteins. J. Biol. Chem. 279, 48607-48614 (2004
45. Chamberlain M. D., et al. Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3 kinase results in cell transformation. J. Biol. Chem. 283, 15861-15868 (2008
46. Chamberlain M. D., et al. Deregulation of Rab5 and Rab4 proteins in p85R274A-expressing cells alters PDGFR trafficking. Cell. Signal. 22, 1562-1575 (2010
47. Kausch C., et al. Association of impaired phosphatidylinositol 3 kinase activity in GLUT1 containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome. J. Clin. Endocrin. Metab. 85, 905-918 (2000
48. Kim S. G., et al. Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT RUVBL1/2 complex. Mol. Cell 49, 172-185 (2013
49. Honda K., et al. Spatiotemporal regulation of MyD88-IRF 7 signalling for robust type I interferon induction. Nature 434, 1035-1040 (2005
50. Caro-Maldonado A., Gerriets V. A., & Rathmell J. C. Matched and mismatched metabolic fuels in lymphocyte function. Semin. Immunol. 24, 405-413 (2012
51. Delgoffe G. M., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295-304 (2011
52. Mercalli A., et al. Rapamycin unbalances the polarization of human macrophages to M1. Immunology 140, 179-190 (2013
53. Zhu L., et al. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat. Commun. 5, 4696 (2014
54. Poglitsch M., et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am. J. Transplant. 12, 1458-1468 (2012
55. Vasheghani F., et al. PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Ann. Rheum. Dis. 74, 569-578 (2015
56. Garcia R. J., et al. Attention deficit and hyperactivity disorder scores are elevated and respond to NAC treatment in patients with SLE. Arthritis Rheum. 65, 1313-1318 (2013
57. Proud C. G. Regulation of mammalian translation factors by nutrients. Eur. J. Biochem. 269, 5338-5349 (2002
58. Duran R., et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol. Cell 47, 349-358 (2012
59. Jewell J. L., et al. Differential regulation of mTORC1 by leucine and glutamine. Science 347, 194-198 (2015
60. Perl A., et al. Comprehensive metabolome analyses reveal N acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics 11, 1157-1174 (2015
61. Duvel K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010
62. Semenza G. L. HIF 1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123, 3664-3671 (2013
63. Liu G., et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF 1 α dependent glycolysis. Cancer Res. 74, 727-737 (2014
64. Ben-Sahra I., Howell J. J., Asara J. M., & Manning B. D. Stimulation of De novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323-1328 (2013
65. Sun Y., et al. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells. Cell Death Dis. 5, e1231 (2014
66. Taylor S. S., Zhang P., Steichen J. M., Keshwani M. M., & Kornev A. P. PKA: lessons learned after twenty years. Biochim. Biophys. Acta 1834, 1271-1278 (2013
67. De Joussineau C., et al. mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). Hum. Mol. Genet. 23, 5418-5428 (2014
68. Yoo S. E., et al. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med. 52, 1820-1827 (2012
69. Xie J., et al. CAMP inhibits mammalian target of rapamycin complex 1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Cell. Signal. 23, 1927-1935 (2011
70. Lai Z. W., et al. N acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum. 64, 2937-2946 (2012
71. Pearce E. L., et al. Enhancing CD8 T cell memory by modulating fatty acid metabolism. Nature 460, 103-107 (2009
72. Michalek R. D., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186, 3299-3303 (2011
73. Spiegel S., & Milstien S. Sphingosine-1 phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell. Biol. 4, 397-407 (2003
74. Rivera J., Proia R. L., & Olivera A. The alliance of sphingosine-1 phosphate and its receptors in immunity. Nat. Rev. Immunol. 8, 753-763 (2008
75. Matloubian M., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004
76. Liu G., et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt- mTOR. Nat. Immunol. 10, 769-777 (2009
77. Liu G., Yang K., Burns S., Shrestha S., & Chi H. The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cells. Nat. Immunol. 11, 1047-1056 (2010
78. Hsieh C. T., Chuang J. H., Yang W. C., Yin Y., & Lin Y. Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle. Cell. Signal. 26, 1400-1408 (2014
79. Yoshida S., et al. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J. Biol. Chem. 286, 32651-32660 (2011
80. Whitman M., Downes C. P., Keeler M., Keller T., & Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3 phosphate. Nature 332, 644-646 (1988
81. Vanhaesebroeck B., Stephens L., & Hawkins P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell. Biol. 13, 195-203 (2012
82. Lamming D. W., et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638-1643 (2012
83. Braccini L., et al. PI3K C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat. Commun. 6, 7400 (2015
84. Kim J., et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 152, 290-303 (2013
85. Worby C. A., & Dixon J. E. PTEN. Annu. Rev. Biochem. 83, 641-669 (2014
86. Sagar V., Bond J. R., & Chowdhary V. R. A 50 year-old woman with Cowden syndrome and joint pains. Arthritis Care Res. 67, 1604-1608 (2015
87. Lee T., Le E. N., Glass D. A., Bowen C. D., & Dominguez A. R. Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome. Brit. J. Dermatol. 170, 990-992 (2014
88. Shrestha S., et al. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16, 178-187 (2015
89. Huynh A., et al. Control of PI3 kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 16, 188-196 (2015
90. Ray J. P., & Craft J. PTENtiating autoimmunity through Treg cell deregulation. Nat. Immunol. 16, 139-140 (2015
91. Wu X. N., et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci. Transl. Med. 6, 246ra99 (2014
92. Bluml S., et al. Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. Ann. Rheum. Dis. 74, 227-233 (2015
93. Inoki K., Zhu T., & Guan K. L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003
94. Gwinn D. M., et al. AMPK phosphorylation of Raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226 (2008
95. Hardie D. G., Carling D., & Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Ann. Rev. Biochem. 67, 821-855 (1998
96. Carroll K. C., Viollet B., & Suttles J. AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J. Leukoc. Biol. 94, 1113-1121 (2013
97. Russell R. C., et al. ULK1 induces autophagy by phosphorylating Beclin 1 and activating VPS34 lipid kinase. Nat. Cell Biol. 15, 741-750 (2013
98. Kang K. Y., et al. Metformin downregulates TH17 cells differentiation and attenuates murine autoimmune arthritis. Int. Immunopharmacol. 16, 85-92 (2013
99. Araki K., et al. mTOR regulates memory CD8 T cell differentiation. Nature 460, 108-112 (2009
100. Rao R. R., Li Q., Odunsi K., & Shrikant P. A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T bet and eomesodermin. Immunity 32, 67-78 (2010
101. Delgoffe G. M., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832-844 (2009
102. Procaccini C., et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33, 929-941 (2010
103. Zeng H., et al. mTORC1 couples immune signals and metabolic programming to establish Treg-cell function. Nature 499, 485-490 (2013
104. Yang Z., Fujii H., Mohan S. V., Goronzy J. J., & Weyand C. M. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J. Exp. Med. 210, 2119-2134 (2013
105. Yang Z., Matteson E. L., Goronzy J. J., & Weyand C. M. T cell metabolism in autoimmune disease. Arthritis Res. Ther. 17, 29 (2015
106. Kato H., & Perl A. Mechanistic taret of rapamycin complex 1 expands TH17 and IL 4+ double negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J. Immunol. 192, 4134-4144 (2014
107. Fernandez D. R., & Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov. Med. 9, 173-178 (2010
108. Moulton V. R., & Tsokos G. C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arth. Res. Ther. 13, 207 (2010
109. Lai Z. W., et al. mTOR activation triggers IL 4 production and necrotic death of double-negative T cells in patients with systemic lupus eryhthematosus. J. Immunol. 191, 2236-2246 (2013
110. Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann. NY Acad. Sci. 1346, 33-44 (2015
111. Tai T. S., Pai S. Y., & Ho I. C. GATA 3 regulates the homeostasis and activation of CD8+ T cells. J. Immunol. 190, 428-437 (2013
112. Tomasoni R., et al. Rapamycin-sensitive signals control TCR/CD28 driven Ifng, Il4 and Foxp3 transcription and promoter region methylation. Eur. J. Immunol. 41, 2086-2096 (2011
113. Sieling P. A., et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J. Immunol. 165, 5338-5344 (2000
114. Shivakumar S., Tsokos G. C., & Datta S. K. T cell receptor α/β expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143, 103-112 (1989
115. Umekawa M., & Klionsky D. J. Ksp1 kinase regulates autophagy via the target of rapamycin complex 1 (TORC1) pathway. J. Biol. Chem. 287, 16300-16310 (2012
116. Odegard J. M., et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL 21 in systemic autoimmunity. J. Exp. Med. 205, 2873-2886 (2008
117. Le Coz C., et al. Circulating TFH subset distribution is strongly affected in lupus patients with an active disease. PLoS ONE 8, e75319 (2013
118. Singh N., Birkenbach M., Caza T., Perl A., & Cohen P. L. Tuberous sclerosis and fulminant lupus in a young woman. J. Clin. Rheumatol. 19, 134-137 (2013
119. Wu T., et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J. Clin. Invest. 117, 2186-2196 (2007
120. Stylianou K., et al. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol. Dial. Transplant. 26, 498-508 (2011
121. Tan E. M., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271-1277 (1982
122. Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997
123. Petri M., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677-2686 (2012
124. Miyakis S., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295-306 (2006
125. Canaud G., et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371, 303-312 (2014
126. Lai Z. W., Marchena-Mendez I., & Perl A. Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome. Clin. Immunol. 158, 148-152 (2015
127. Doherty E., Oaks Z., & Perl A. Increased mitochondrial electron transport chain activity at complex I is regulated by N acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antiox. Redox Signal. 21, 56-65 (2014
128. Yin Y., et al. Normalization of CD4+ T cell metabolism reverses lupus. Sci. Transl. Med. 7, 274ra18 (2015
129. Hanczko R., et al. Prevention of hepatocarcinogenesis and acetaminophen-induced liver failure in transaldolase-deficient mice by N acetylcysteine. J. Clin. Invest. 119, 1546-1557 (2009
130. Perl A., Hanczko R., Telarico T., Oaks Z., & Landas S. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol. Med. 7, 395-403 (2011
131. Malemud C. J. The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? Future Med. Chem. 7, 1137-1147 (2015
132. Messaoudi I., Warner J., & Nikolich-Zugich J. Age related CD8+ T cell clonal expansions express elevated levels of CD122 and CD127 and display defects in perceiving homeostatic signals. J. Immunol. 177, 2784-2792 (2006
133. Laragione T., & Gulko P. S. mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol. Med. 16, 352-358 (2010
134. Saxena A., Raychaudhuri S. K., & Raychaudhuri S. P. Interleukin-17 induced proliferation of fibroblast-like synovial cells is mTOR dependent. Arthritis Rheum. 63, 1465-1466 (2011
135. Reveille J. D. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin. Rheumatol. 34, 1009-1018 (2015
136. International Genetics of Ankylosing Spondylitis Consortium (IGAS), et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45, 730-738 (2013
137. Robinson P. C., et al. ERAP2 is associated with ankylosing spondylitis in HLA B27 positive and HLA B27 negative patients. Ann. Rheum. Dis. 74, 1627-1629 (2015
138. Evans D. M., et al. Interaction between ERAP1 and HLA B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA B27 in disease susceptibility. Nat. Genet. 43, 761-767 (2011
139. Appel H., et al. In situ analysis of interleukin 23 and interleukin 12 positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 65, 1522-1529 (2013
140. Lai N. S., et al. Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis. Clin. Exp. Immunol. 173, 47-57 (2013
141. Hou C., Zhu M., Sun M., & Lin Y. MicroRNA let 7i induced autophagy to protect T cell from apoptosis by targeting IGF1R. Biochem. Biophys. Res. Commun. 453, 728-734 (2014
142. Kooijman R., Lauf J. J., Kappers A. C., & Rijkers G. T. Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol 3 kinase in human thymocytes. J. Exp. Med. 182, 593-597 (1995
143. Kooijman R., Scholtens L. E., Rijkers G. T., & Zegers B. J. Differential expression of type I insulin like growth factor receptors in different stages of human T cells. Eur. J. Immunol. 25, 931-935 (1995
144. Xu W. D., et al. Up regulation of fatty acid oxidation in the ligament as a contributing factor of ankylosing spondylitis: a comparative proteomic study. J. Proteom. 113, 57-72 (2015
145. Mease P. J. Inhibition of interleukin 17, interleukin 23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr. Opin. Rheumatol. 27, 127-133 (2015
146. Helms C., et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 35, 349-356 (2003
147. Mitra A., Raychaudhuri S. K., & Raychaudhuri S. P. IL 22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 60, 38-42 (2012
148. Peled M., et al. Analysis of programmed death 1 in patients with psoriatic arthritis. Inflammation 38, 1573-1579 (2015
149. Javier A. F., et al. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J. Clin. Invest. 99, 2094-2099 (1997
150. Buerger C., Malisiewicz B., Eiser A., Hardt K., & Boehncke W. H. Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin. Br. J. Dermatol. 169, 156-159 (2013
151. Young C. N., et al. Reactive oxygen species in tumor necrosis factor-α activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J. Invest. Dermatol. 128, 2606-2614 (2008
152. Wynn T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008
153. Wilkes M. C., et al. Transforming growth factor β activation of phosphatidylinositol 3 kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21 activated kinase 2. Cancer Res. 65, 10431-10440 (2005
154. Rahimi R. A., et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor β. Cancer Res. 69, 84-93 (2009
155. Li J., et al. Rictor/mTORC2 signaling mediates TGFβ1 induced fibroblast activation and kidney fibrosis. Kidney Int. 88, 515-527 (2015
156. Brandt K. D., Dieppe P., & Radin E. Etiopathogenesis of osteoarthritis. Med. Clin. North Am. 93, 1-24 (2009
157. Guan Y., Yang X., Yang W., Charbonneau C., & Chen Q. Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development. FASEB J. 28, 4470-4481 (2014
158. Lotz M., & Carames B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and osteoarthritis. Nat. Rev. Rheumatol. 7, 579-587 (2011
159. Zhang Y., et al. Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. Ann. Rheum. Dis. 74, 1432-1440 (2015
160. Harrison D. E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009
161. Sabatini D. M., Erdjument-Bromage H., Lui M., Tempst P., & Snyder S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35-43 (1994
162. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov
163. Chiarini F., Evangelisti C., McCubrey J. A., & Martelli A. M. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharm. Sci. 36, 124-135 (2015
164. Thoreen C. C., et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009
165. Dancey J. E. Therapeutic targets: mTOR and related pathways. Cancer Biol. Ther. 5, 1065-1073 (2006
166. Peng L., Zhou Y., Ye X., & Zhao Q. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer meta-analysis of clinical trials. Tumor Biol. 36, 643-654 (2014
167. Markman B., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3 kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23, 2399-2408 (2012
168. Aghdasi B., et al. FKBP12, the 12 kDa FK506 binding protein, is a physiologic regulator of the cell cycle. Proc. Natl Acad. Sci. USA 98, 2425-2430 (2001
169. Dolinski K., Muir S., Cardenas M., & Heitman J. All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 94, 13093-13098 (1997
170. Houde V. P., et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59, 1338-1348 (2010
171. Fraenkel M., et al. mTOR inhibition by rapamycin prevents β cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57, 945-957 (2008
172. Fang Y., et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell. Metab. 17, 456-462 (2013
173. Schenone S., Brullo C., Musumeci F., Radi M., & Botta M. ATP-competitive inhibitors of mTOR: an update. Curr. Med. Chem. 18, 2995-3014 (2011
174. Wang B. T., et al. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc. Natl Acad. Sci. USA 108, 15201-15206 (2011
175. Ramos-Barron A., et al. Prevention of murine lupus disease in (NZB × NZW)F1 mice by sirolimus treatment. Lupus 16, 775-781 (2007
176. Lui S. L., et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol. Dial. Transplant. 23, 2768-2776 (2008
177. Yap D. Y., Ma M. K., Tang C. S., & Chan T. M. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton) 17, 676-680 (2012
178. US National Library of Medicine. NCT00779194. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/results?term=NCT00779194 (2015
179. Reitamo S., et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Brit. J. Dermatol. 145, 438-445 (2001
180. Niculescu F., et al. Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3 kinase and mitogen-activated protein kinase pathways. Arthritis Rheum. 48, 1071-1079 (2003
181. Barber D. F., et al. PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935 (2005
182. Suarez-Fueyo A., Barber D. F., Martinez-Ara J., Zea Mendoza A. C., & Carrera A. C. Enhanced phosphoinositide 3 kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J. Immunol. 187, 2376-2385 (2011
183. Suarez-Fueyo A., et al. Inhibition of PI3Kγ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J. Immunol. 193, 544-554 (2014
184. Chen H., et al. Leptin and NAP2 promote mesenchymal stem cell senescence through activation of PI3K/Akt pathway in patients with systemic lupus erythematosus. Arthritis Rheumatol. 67, 2383-2393 (2015
185. Bartok B., et al. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. Am. J. Pathol. 180, 1906-1916 (2012
186. Perl A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat. Rev. Rheumatol. 9, 674-686 (2013
187. Gergely P. J., et al. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL 10 signaling in patients with systemic lupus erythematosus. J. Immunol. 169, 1092-1101 (2002
188. Li Y., Gorelik G., Strickland F. M., & Richardson B. C. Oxidative stress, T cell DNA methylation and lupus. Arthritis Rheum. 66, 1574-1582 (2014
189. Gehrke N., et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 39, 482-495 (2013
190. Scofield R. H., et al. Modification of lupus-associated 60 kDa Ro protein with the lipid oxidation product 4 hydroxy-2 nonenal increases antigenicity and facilitates epitope spreading. Free Radic. Biol. Med. 38, 719-728 (2005
191. Otaki N., et al. Identification of a lipid peroxidation product as the source of oxidation-specific epitopes recognized by anti-DNA autoantibodies. J. Biol. Chem. 285, 33834-33842 (2010
192. Gergely P. J., et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 46, 175-190 (2002
193. Shah D., Aggarwal A., Bhatnagar A., Kiran R., & Wanchu A. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic. Res. 45, 559-567 (2011
194. Shah D., Kiran R., Wanchu A., & Bhatnagar A. Oxidative stress in systemic lupus erythematosus: relationship to TH1 cytokine and disease activity. Immunol. Lett. 129, 7-12 (2010
195. Li K. J., et al. Deranged bioenergetics and defective redox capacity in T lymphocytes and neutrophils are related to cellular dysfunction and increased oxidative stress in patients with active systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 548516 (2012
196. Nambiar M. P., et al. Oxidative stress is involved in the heat stress-induced downregulation of TCRζ chain expression and TCR/CD3 mediated [Ca2+]i response in human T lymphocytes. Cell. Immunol. 215, 151-161 (2002
197. Suwannaroj S., Lagoo A., Keisler D., & McMurray R. W. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 10, 258-265 (2001
198. Bergamo P., et al. Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/MpJ-Faslpr mice. J. Lipid Res. 47, 2382-2391 (2006
199. Bergamo P., Maurano F., & Rossi M. Phase 2 enzyme induction by conjugated linoleic acid improves lupus-associated oxidative stress. Free Radic. Biol. Med. 43, 71-79 (2007
200. Herzenberg L. A., et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl Acad. Sci. USA 94, 1967-1972 (1997
201. Travaline J. M., et al. Effect of N acetylcysteine on human diaphragm strength and fatigability. Am. J. Resp. Crit. Care Med. 156, 1567-1571 (1997
202. Demedts M., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229-2242 (2005
203. Brattstrom C., et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65, 1272-1274 (1998
204. Qi W. X., Huang Y. J., Yao Y., Shen Z., & Min D. L. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS ONE 8, e65166 (2013
205. Trager J., & Ward M. M. Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13, 345-351 (2001
206. Lee R., Margaritis M., Channon K. M., & Antoniades C. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr. Med. Chem. 19, 2504-2520 (2012
207. Tepel M., Van Der Giet M., Statz M., Jankowski J., & Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 107, 992-995 (2003
208. Kim Y. C., & Guan K. L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest. 125, 25-32 (2015
209. Yan H., Zhou H. F., Hu Y., & Pham C. T. Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. J. Rheum. Dis. Treat. 1, 5 (2015
210. Martinet W., De Loof H., & De Meyer G. R. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 233, 601-607 (2014
211. Balasubramaniam S., et al. Novel heterozygous mutations in TALDO1 gene causing transaldolase deficiency and early infantile liver failure. J. Pediatr. Gastroenterol. Nutr. 52, 113-116 (2011
212. Taniguchi M., et al. Regulation of autophagy and its associated cell death by sphingolipid rheostat: reciprocal role of ceramide and sphingosine 1 phosphate in the mammalian target of rapamycin pathway. J. Biol. Chem. 287, 39898-39910 (2012
213. Brinkmann V., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 (2010
214. Okazaki H., et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. 29, 707-716 (2002
215. Wenderfer S. E., Stepkowski S. M., & Braun M. C. Prolonged survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1 P receptor agonist. Kidney Int. 74, 1319-1326 (2008
216. Koga T., et al. CaMK4 dependent activation of AKT/mTOR and CREM α underlies autoimmunity-associated TH17 imbalance. J. Clin. Invest. 124, 2234-2245 (2014
217. Koga T., et al. KN 93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3+ regulatory T cells in MRL/lpr mice. Autoimmunity 47, 445-450 (2014
218. Ichinose K., Juang Y. T., Crispin J. C., Kis-Toth K., & Tsokos G. C. Inhibition of calcium/calmodulin-dependent protein kinase type IV results in suppression of autoimmunity and organ pathology in lupus-prone mice. Arthritis Rheum. 63, 523-529 (2011
219. Fujikawa K., et al. Calcium/calmodulin-dependent protein kinase II (CaMKII) regulates tumour necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells (FLS) by phosphorylation of Akt. Clin. Exp. Rheumatol. 27, 952-957 (2009
220. Westra J., et al. Expression and regulation of HIF 1α in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet. Disord. 11, 61 (2010
221. Yepuri G., et al. Positive crosstalk between arginase II and S6K1 in vascular endothelial inflammation and aging. Aging Cell 11, 1005-1016 (2012
222. Xiong Y., et al. ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis. Autophagy 10, 2223-2238 (2014
223. Elloso M. M., et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E deficient mice. Am. J. Transplant. 3, 562-569 (2003
224. Manzi S., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 145, 408-415 (1997
225. Mackey R. H., et al. Rheumatoid arthritis, anti-CCP positivity, and cardiovascular disease risk in the Womens Health Initiative. Arthritis Rheumatol. 67, 2311-2322 (2015
226. Avina-Zubieta J. A., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Care Res. 59, 1690-1697 (2008
227. Soefje S. A., Karnad A., & Brenner A. J. Common toxicities of mammalian target of rapamycin inhibitors. Target. Oncol. 6, 125-129 (2011
228. Doran M. F., Crowson C. S., Pond G. R., OFallon W. M., & Gabriel S. E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46, 2287-2293 (2002
229. Paul M., et al. Methotrexate promotes platelet apoptosis via JNK-mediated mitochondrial damage: alleviation by N acetylcysteine and N acetylcysteine amide. PLoS ONE 10, e0127558 (2015
230. Laplante M., & Sabatini D. M. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell Sci. 126, 1713-1719 (2013
231. Lui S. L., et al. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 17, 305-313 (2008
232. Kshirsagar S., et al. Akt-dependent enhanced migratory capacity of TH17 cells from children with lupus nephritis. J. Immunol. 193, 4895-4903 (2014
233. Tian J., Wang Y., Liu X., Zhou X., & Li R. Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms. Exp. Biol. Med. (Maywood) 240, 936-945 (2015
234. Cruzado J. M., et al. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol. Dial. Transplant. 26, 3596-3602 (2011
235. Zou Y., et al. Oligodendrocyte precursor cell-intrinsic effect of Rheb1 controls differentiation and mediates mTORC1-dependent myelination in brain. J. Neurosci. 34, 15764-15778 (2014
236. Seyfarth H. J., Hammerschmidt S., Halank M., Neuhaus P., & Wirtz H. R. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. Pulm. Circ. 3, 632-638 (2013
237. Raychaudhuri S. K., & Raychaudhuri S. P. mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target. Indian J. Dermatol. 59, 67-70 (2014
238. Mitra A., et al. Dual mTOR inhibition is required to prevent TGF β mediated fibrosis: implications for scleroderma. J. Invest. Dermatol. 135, 2873-2876 (2015
239. Biniecka M., et al. Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis. Arth. Rheum. 63, 2172-2182 (2011
240. Nahir A
241. Walters M. T., Rubin C. E., & Keightley S. J. A double-blind, cross-over, study of oral N acetylcysteine in Sjögrens syndrome. 15, 253-258 (1986
242. Kelly C., & Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Exp. Opin. Pharmacother. 9, 3221-3230 (2008
243. Son H. J., et al. Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of TH17/Treg balance and osteoclastogenesis. Mediators Inflamm. 2014, 973986 (2014